Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion-Positive Breast Cancer.

ABSTRACT:

SUBMITTER: Watanabe S 

PROVIDER: S-EPMC8140803 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature